SpringWorks Therapeutics Inc (SWTX)

Schlusskurs vom Vortag:

$44.20

Offen:

$44.04

24-Stunden-Volumen:

877.94K

Marktkapitalisierung:

$3.37B

Einnahmen:

-

Nettoeinkommen (Verlust:

$-325.10M

KGV:

-9.3491

EPS:

-4.87

Netto-Cashflow:

$-230.18M

1W Leistung:

+13.54%

1M Leistung:

-7.46%

6M Leistung:

+100.13%

1J Leistung:

+95.83%

1-Tages-Spanne:

$43.44

$46.04

52-Wochen-Spanne:

$18.00

$53.92

SpringWorks Therapeutics Inc Stock (SWTX) Company Profile

Firmenname

SpringWorks Therapeutics Inc

Sektor

Healthcare (1191)

Branche

Biotechnology (688)

Telefon

203 883 9490

Adresse

100 Washington Boulevard, Stamford, CT

Mitarbeiter

60

Twitter

@springworkstx

Nächster Verdiensttermin

2024-05-16

Neueste SEC-Einreichungen

SWTX's Discussions on Twitter

SpringWorks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-02-05	Eingeleitet	Guggenheim	Buy
2022-12-01	Eingeleitet	BofA Securities	Buy
2021-01-19	Bestätigt	H.C. Wainwright	Buy
2020-10-29	Bestätigt	H.C. Wainwright	Buy
2020-05-05	Eingeleitet	Barclays	Overweight
2020-03-19	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-03-04	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-01-21	Bestätigt	H.C. Wainwright	Buy
2019-12-04	Eingeleitet	H.C. Wainwright	Buy
2019-10-08	Eingeleitet	Cowen	Outperform
2019-10-08	Eingeleitet	Goldman	Buy
2019-10-08	Eingeleitet	JP Morgan	Overweight
2019-10-08	Eingeleitet	Wedbush	Outperform

Alle ansehen

SpringWorks Therapeutics Inc Aktie (SWTX) Neueste Nachrichten

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire Inc.

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

GlobeNewswire Inc.

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

GlobeNewswire Inc.

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

GlobeNewswire Inc.

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

GlobeNewswire Inc.

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire Inc.

Finanzdaten der SpringWorks Therapeutics Inc-Aktie (SWTX)

SpringWorks Therapeutics Inc (SWTX) Nettogewinn 2024

SpringWorks Therapeutics Inc (SWTX) Free Cashflow 2024

SpringWorks Therapeutics Inc (SWTX) Gewinn je Aktie 2024